Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders
28 March, 2022
Heidelberg, 10 March 2022 Molecular Health and collaborators at the University of Florida College of Pharmacy, Takeda Oncology, and thinkQ² published a triad of articles that describe and prove the concept of a novel systems approach to elucidate molecular mechanisms of drug toxicities using real-world data (RWD).
10 March, 2022